Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
March 02 2018 - 7:00AM
Business Wire
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced that it will
present clinical data from two Phase 1 studies of its norovirus
oral tablet vaccine at the upcoming 18th International Congress on
Infectious Diseases (ICID), taking place from March 1-4, 2018 in
Buenos Aires, Argentina.
“The clinical data to be presented at ICID demonstrate that our
orally administered norovirus tablet vaccine was well-tolerated and
generated robust systemic and local intestinal immune responses,”
said Sean Tucker, Ph.D., founder and chief scientific officer of
Vaxart. “We believe the quality of the intestinal responses,
including both memory and local effector IgA B-cell responses, is
unique to our platform and could lead to superior efficacy against
an enteric pathogen such as norovirus. Importantly, we did not see
any evidence of anti-vector immunity with our oral vaccine, another
unique feature of our platform and a potential key advantage over
injectable vectored vaccines.”
Presentation Title: Oral immunization of a rAd vector
expressing norovirus VP1 elicits a potent mucosal immune response
without an increase in anti-vector immunityDate & Time:
Saturday, March 3, 2018 from 5:00 – 6:00 PM ARTAuthors: Sean
Tucker, et al.Session: Zoonoses
All recent presentations are available on the Vaxart website
under Newsroom at www.vaxart.com.
About Vaxart
Vaxart is a clinical-stage company focused on developing oral
recombinant protein vaccines based on its proprietary oral vaccine
platform and direct-acting antivirals to treat infections that have
limited therapeutic options. Vaxart’s oral vaccines are designed to
generate broad and durable immune responses that protect against a
wide range of infectious diseases and may be useful for the
treatment of chronic viral infections and cancer. Vaxart’s oral
vaccines are administered using a convenient room
temperature-stable tablet, rather than by injection. Vaxart
believes that tablet vaccines are easier to distribute and
administer than injectable vaccines, and have the potential to
significantly increase vaccination rates. Vaxart’s development
programs include oral tablet vaccines that are designed to protect
against norovirus, seasonal influenza and respiratory syncytial
virus (RSV), as well as a therapeutic vaccine for human
papillomavirus (HPV). Through the merger, Vaxart also acquired
antiviral drug candidates, including teslexivir (BTA074), an
antiviral treatment for condyloma caused by HPV types 6 and 11. For
more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, beliefs
and expectations of management are forward-looking statements.
These forward-looking statements may be accompanied by such words
as “believe,” “could,” “potential” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to Vaxart’s ability to develop its
pipeline of proprietary oral vaccines and direct-acting virals, as
well as the anticipated timing of value creating events. Vaxart may
not actually achieve the plans, carry out the intentions or meet
the expectations or projections disclosed in our forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Vaxart makes, that
Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; and the risks described in the
“Risk Factors” sections of the Registration Statement on Form S-4
(file no. 333-222009) and of Vaxart’s periodic reports filed with
the SEC. Vaxart does not assume any obligation to update any
forward-looking statements, except as required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180302005118/en/
W2OKatie Hogan, 415-658-9745khogan@wcgworld.comorStern Investor
RelationsCarl Mauch, 212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024